Newly diagnosed multiple myeloma (MM) patients requiring salvage therapy prior to high dose therapy (HDT) have equivalent progression free survival and overall survival to those receiving a single induction regimen

被引：0
|
作者：
Percy, L. A. [1 ]
Rabin, N. [1 ]
Qian, W. [2 ]
Moore, S. [1 ]
Symeonidis, A. [3 ]
Dorman, J. [1 ]
Quinn, J. [1 ]
Ings, S. [1 ]
Watts, M. [1 ]
Linch, D. [1 ]
Yong, K. [1 ]
机构：
[1] Univ Coll London Hosp, Dept Haematol, London, England
[2] MRC Clin Trials Unit, London, England
[3] Univ Patras, Sch Med, Dept Haematol, GR-26110 Patras, Greece
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 149卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [1] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
    Sorrig, Rasmus
    Klausen, Tobias W.
    Salomo, Morten
    Vangsted, Annette J.
    Frolund, Ulf Christian
    Andersen, Kristian T.
    Klostergaard, Anja
    Helleberg, Carsten
    Pedersen, Robert S.
    Pedersen, Per T.
    Helm-Petersen, Sissel
    Teodorescu, Elena Manuela
    Preiss, Birgitte
    Abildgaard, Niels
    Gimsing, Peter
    PLOS ONE, 2017, 12 (12):
  • [2] Induction therapy with high-dose dexamethasone alone in newly diagnosed myeloma patients produces a high partial response rate which is predictive of progression free and overall survival
    Irvine, D. A.
    Barnett, M. J.
    Brinkman, R.
    Forrest, D. L.
    Hogge, D. E.
    Lavoie, J.
    Lei, L.
    Nantel, S. H.
    Nevill, T. J.
    Nitta, J.
    Shepherd, J.
    Song, K.
    Smith, C. A.
    Toze, C.
    Sutherland, H. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 38 - 38
  • [3] Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Meddour, Yanis
    Rahali, Momahed C.
    Belakehal, Salah E.
    Ardjoun, Fatma Z.
    Chaib, Samia
    Djidjik, Reda
    CLINICAL LABORATORY, 2018, 64 (04) : 551 - 558
  • [4] Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival
    Palumbo, Antonio
    Attal, Michel
    Roussel, Murielle
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1253 - 1263
  • [5] Induction therapy with high-dose dex alone in newly diagnosed myeloma patients produces a 57% partial response and is predictive of progression free survival.
    Irvine, David A.
    Barnett, Michael J.
    Brinkman, Ryan
    Forrest, Donna L.
    Hogge, Donna E.
    Lavoie, Julve
    Lei, Linda
    Nantel, Stephen H.
    Nevill, Thomas J.
    Nitta, Janet
    Shepherd, John
    Song, Kevin
    Toze, Cynthia
    Sutherland, Heather
    BLOOD, 2006, 108 (11) : 883A - 883A
  • [6] Effect of induction regimen in survival in newly diagnosed multiple myeloma patients receiving consolidation with autologous stem cell transplantation
    Garrido, David
    von Glassenap, Alana
    Pena, Camila
    Martinez-Cordero, Humberto
    Ramirez-Alvarado, Aline
    Tarin-Arzaga, Luz
    Schutz, Natalia
    Bove, Virginia
    Sossa, Claudia
    Yantorno, Sebastian
    Ochoa, Paola
    Orlando, Sergio
    Ladines-Castro, Washington
    Duarte, Patricio
    Remaggi, Guillermina
    Shanley, Claudia
    Ruiz-Arguelles, Guillermo
    Fantl, Dorotea
    Riva, Eloisa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S132 - S133
  • [7] Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
    Nooka, Ajay K.
    Behera, Madhusmita
    Boise, Lawrence H.
    Watson, Melanie
    Kaufman, Jonathan L.
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 807 - 808
  • [8] Impact of interferon maintenance therapy on multiple myeloma patients' quality of life, progression-free survival and overall survival
    Bumeder, I
    Tyroller, M.
    Fischer, N.
    Busch, R.
    Frick, E.
    PSYCHO-ONCOLOGY, 2006, 15 (02) : S187 - S188
  • [9] Impact of Duration of Induction Therapy on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation
    Chakraborty, Rajshekar
    Muchtar, Eli
    Kumar, Shaji K.
    Buadi, Francis K.
    Dingli, David
    Dispenzieri, Angela
    Haymann, Suzanne
    Hogan, William J.
    Kapoor, Prashant
    Lacy, Martha Q.
    Leung, Nelson
    Warsame, Rahma
    Kourelis, Taxiarchis
    Gonsalves, Wilson I.
    Gertz, Morie A.
    BLOOD, 2017, 130
  • [10] Real-World Comparison of Progression Free Survival and Time to Next Therapy Endpoints in Newly Diagnosed Patients With Multiple Myeloma
    Mutterback, Erin
    Mian, Hira
    McCurdy, Arleigh
    Cipkar, Christopher
    Sapru, Hyra
    Fonseca, Rafael
    Visram, Alissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S237 - S238
12345